ZOvCa: A phase 1 Positron Emission Tomography (PET) - Computed Tomography (CT) study to evaluate the safety, biodistribution and pharmacokinetics of 89Zr-hu/mo-10D7 in patients with advanced epithelial Ovarian Cancer

Ovarian cancer is one of the most difficult cancers to treat, partly because it is often not caught until it has spread. This early-phase study is testing a new imaging agent called 89Zr-hu/mo-10D7, which is designed to "light up" ovarian cancer tumours on a PET-CT scan by targeting a protein called CDCP1 that is found on ovarian cancer cells. The goal is to see whether this agent can accurately find cancer deposits in the body and to understand how it behaves once administered. All participants will receive a single intravenous infusion of the imaging agent and then be monitored with blood tests, vital signs checks, ECGs, urine tests, and PET-CT scans over the following days. No cancer treatment is being tested in this study — it is purely an imaging investigation. You may be eligible if you are a woman aged 18 or older with recurrent, histologically confirmed advanced ovarian cancer, with visible tumour on diagnostic imaging, a CDCP1-positive tumour sample, good general health (ECOG 0 to 1), and a life expectancy of more than 3 months. Any cancer treatment received in the last 28 days would make you ineligible.